No Data
No Data
Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Verve Therapeutics, Inc. (VERV): Is This Gene Therapy Stock a Good Buy Right Now?
Verve Therapeutics Slides As Insider Purchases Lose Another US$65k
Stifel Maintains Verve Therapeutics(VERV.US) With Buy Rating
Stifel Nicolaus Sticks to Their Buy Rating for Verve Therapeutics (VERV)
Verve Therapeutics Has Positive Read From NewAmsterdam Data, Says Stifel
No Data